Learn how CMS is trying to change drug prior authorization, speed up prescription approvals, and reduce insurance delays. Learn why this matters for patient access, healthcare transparency, Medicare, Medicaid, marketplace plans, and the way prescription coverage decisions are made.
CMS Drug Rules Explained – How They Could Reduce Prescription Delays
🆓Help finding a Medicare plan is ALWAYS FREE! Call 615-639-1937 for our Medicare partner, Chapter Medicare or click here
New CMS Drug Rules Explained
The Centers for Medicare & Medicaid Services, or CMS, has proposed a new rule that could change how prescription drug prior authorization works across major health plans. The goal is to speed up decisions, expand electronic processing, and give the public more visibility into how approvals and denials happen.
This matters because prior authorization often sits between a doctor writing a prescription and a patient getting the medicine. When that process is slow or hard to track, treatment can be delayed and provider offices can get buried in paperwork. CMS is trying to reduce those delays without getting rid of prior authorization entirely.
What Changed
CMS has proposed a rule called the Interoperability Standards and Prior Authorization for Drugs proposed rule. It would apply to Medicare Advantage organizations, state Medicaid fee for service programs, Medicaid managed care plans, CHIP agencies and CHIP managed care entities, Qualified Health Plan issuers on the federally facilitated exchanges, and some small group marketplace plans.
The rule would require impacted payers to support electronic prior authorization for drugs, update health IT standards, and report interoperability API endpoints and usage metrics to CMS. It would also expand public reporting on drug prior authorization decisions.
Key Details
One of the biggest changes is the push for faster decisions. CMS says the proposal would align programs around shorter decision timeframes, but the exact timeline depends on the payer type.
For Qualified Health Plans on the federally facilitated exchanges, the proposed timeframe is no later than 72 hours for standard requests and 24 hours for expedited requests for drugs. For Medicaid and CHIP-related programs, some covered outpatient drug requests can be subject to a 24-hour timeframe, while some items and services rules remain at 7 days for standard requests and 72 hours for expedited requests.
That means there is not one single deadline for every plan. The broad message is that CMS wants drug prior authorization decisions to move faster and more consistently, but the details vary by program.
More Transparency
Another major part of the proposal is public reporting. CMS says impacted payers would have to report drug prior authorization metrics such as approval rates, denial rates, appeal outcomes, and decision timeframes.
That could make the system easier to evaluate. Patients, providers, and policymakers may get a clearer picture of how different plans handle requests and how often decisions are overturned on appeal.
How This Fits Into Earlier Rules
This proposal does not stand alone. CMS says it builds on earlier interoperability and prior authorization rules from 2020 and 2024. The 2024 final rule focused on electronic prior authorization for many non-drug items and services. This new proposal extends that effort to drugs covered under a medical benefit.
CMS is presenting this as part of a broader modernization effort across the healthcare system. The agency says it wants to replace fragmented workflows with more connected digital systems so patients can get timelier answers and providers can spend less time on manual tasks.
What This Means for You
If this rule is finalized, it could make some prescription approval decisions faster and easier to track. It could also make health plans more transparent by showing more data about how they handle prior authorization.
At the same time, prior authorization would still exist. This proposal changes how the process works, but it does not end the review system itself. So the possible benefit is not automatic approval. The possible benefit is a process that is faster, more digital, and easier to understand.
Why CMS Says It Matters
CMS Administrator Dr. Mehmet Oz said patients should not have to wait days or weeks for approval to start the medication their doctor prescribed. CMS also said the proposal is meant to move prior authorization into the digital age by reducing reliance on fragmented systems and manual workflows.
That is important because delays do not only affect patients. They also affect doctor offices, pharmacy teams, and staff who spend time chasing records, resending forms, and checking decisions. CMS is trying to reduce that administrative burden while still keeping prior authorization in place.
What Happens Next
This is still a proposed rule, not a final one. It has entered the federal rulemaking process and is open for public comment.
That means insurers, provider groups, patient advocates, and others can still weigh in before the rule is finalized. Some parts could change before any final requirements take effect.
Frequently Asked Questions
What is CMS proposing for drug prior authorization?
CMS is proposing faster, more electronic, and more transparent prior authorization rules for drugs across several public and marketplace health plans.
Will prior authorization go away under this proposal?
No. CMS is not proposing to eliminate prior authorization. It is proposing to improve how the process works.
Will every plan have the same deadline?
No. The proposed timelines vary depending on the payer type. Some plans would follow 72-hour and 24-hour deadlines, while others have different standards.
Could this help reduce prescription delays?
That is the goal of the proposal. CMS says it wants to shorten decision clocks, expand electronic prior authorization, and reduce administrative burden.
What new information would plans have to report?
CMS says plans would have to report metrics such as approval rates, denial rates, appeal outcomes, and decision timeframes for drug prior authorization.
Is the rule final now?
No. It is still in the proposed stage and open for public comment.
What to Remember
The main takeaway is simple. CMS is trying to make drug prior authorization faster, more digital, and easier to evaluate.
The details depend on the type of plan, and the rule is not final yet. But the proposal shows that prescription delays and administrative friction are now being treated as central healthcare access issues, not just background paperwork.
Money Instructor does not provide tax, legal, or investment advice. This material has been prepared for educational and informational purposes only, and is not intended to provide, and should not be relied on for, tax, legal or investment advice. You should consult your own tax, legal, and investment advisors regarding your own financial situation. Although the information has been researched and vetted beforehand, it may not be current at the time of viewing. Please note, the context of financial investments can be complex and dynamic, necessitating professional advice tailored to your unique circumstances.
Disclosure: We may receive a referral fee from Chapter if you choose to use their service. Chapter is a licensed health insurance agency and is not affiliated with or endorsed by Medicare or any government agency.
